Germline polymorphism of cancer susceptibility genes in gynecologic cancer

Human Cell

Volumn 21, Issue 4, 2008, Pages 95-104

  Ueda, Masatsugu ^a   Toji, Eisaku ^a   Nunobiki, Osamu ^a   Izuma, Shinji ^a   Okamoto, Yoshiaki ^a   Torii, Kiyo ^a   Noda, Sadamu ^a  

^a Osaka Cancer Prevention and Detection Center   (Japan)

Author keywords

FAS CD95; Glutathione S transferase; Gynecologic cancer; p53; Polymorphism

Indexed keywords

FAS ANTIGEN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; PROTEIN P53;

CANCER RISK; CANCER SUSCEPTIBILITY; CODON; DNA POLYMORPHISM; ENDOMETRIUM CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER;

ALLELES; ANTIGENS, CD95; CODON; DNA; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENITAL NEOPLASMS, FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 56549106232     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1111/j.1749-0774.2008.00058.x     Document Type: Review

References (79)

1. Tsigris C, Chatzitheofylaktou A, Xiromeritis C et al. Genetic association studies in digestive system malignancies. Anticancer Res 2007 27 : 3577 87.
2. Ueda M, Hung YC, Terai Y et al. Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 2003 16 : 241 51.
3. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994 54 : 4313 20.
4. Singhal SS, Zimniak P, Awasthi S et al. Several closely related glutathione S-transferase isoenzymes catalysing conjugation of 4-hydroxynonenal are differentially expressed in human tissues. Arch Biochem Biophys 1994 311 : 242 50.
5. Baez S, Segura-Aguilar J, Widersten M et al. Glutathione transferases catalyse the detoxification of oxidised metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997 324 : 25 8.
6. Wiencke JK, Kelsey KT, Lamela RA et al. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 1990 50 : 1585 90.
7. Schroeder KR, Wibel FA, Reich S et al. Glutathione S-transferase (GST) θ polymorphism influences background SCE rate. Arch Toxicol 1995 69 : 505 7.
8. Nazar-Stewart V, Motulsky AG, Eaton DL et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993 53 : 2313 18.
9. Hirvonen A, Husgafvel-Pursiainen K, Anttila S et al. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis (Lond) 1993 14 : 1479 81.
10. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis (Lond) 1994 15 : 415 18.
11. Cheng L, Sturgis EM, Eicher SA et al. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999 84 : 220 4.
12. Jourenkova N, Reinikainen M, Bouchardy C et al. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prevent 1998 7 : 19 23.
13. Ambrosone CB, Sweeney C, Coles BF et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001 61 : 7130 5.
14. Howells REJ, Redman CWE, Dhar KK et al. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1998 4 : 2439 45.
15. Wang L, Groves MJ, Hepburn MD et al. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. Haematologica 2000 85 : 573 9.
16. Meyer DJ, Christodoulides LG, Hong-Tan K et al. Isolation, properties and tissue distribution of rat glutathione transferase E. FEBS Lett 1984 173 : 327 30.
17. Chen H, Sandler DP, Taylor JA et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996 347 : 295 7.
18. Elexpuru-Camiruaga J, Buxton N, Kandula V et al. Susceptibility to astrocytoma and meningioma. Influence of allelism at glutathione S-transferase GSTT1 and GSTM1 and cytochrome P450 CYP2D6 loci. Cancer Res 1995 55 : 4237 9.
19. Kim JW, Lee CG, Park YG et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 2000 88 : 2082 91.
20. Sharma A, Sharma JK, Murthy NS et al. Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population. Neoplasma 2004 51 : 12 16.
21. Sobti RC, Kaur S, Kaur P et al. Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India. Cancer Genet Cytogenet 2006 166 : 177 23.
22. Spurdle AB, Webb PM, Purdie DM et al. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 2001 22 : 67 72.
23. Beeghly A, Katsaros D, Chen H et al. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 2006 100 : 330 7.
24. Morari EC, Lima AB, Bufalo NE et al. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 2006 132 : 521 8.
25. Nagle CM, Chenevix-Trench G, Spurdle AB et al. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007 43 : 283 90.
26. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996 6 : 187 91.
27. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarks Prev 1998 7 : 537 44.
28. Goodman MT, McDuffie K, Hernandez B et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol 2001 81 : 263 9.
29. Warwick A, Sarhanis P, Redman C et al. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: interactions with GSTM1, CYP2D6 and smoking. Carcinogenesis 1994 15 : 2841 5.
30. Chen C, Madeleine MM, Weiss NS et al. Glutathione S-transferase M1 genotypes and the risk of squamous carcinoma of the cervix: a population-based case-control study. Am J Epidemiol 1999 150 : 568 72.
31. Nagata S, Golstein P. The Fas death factor. Science 1995 267 : 1449 56.
32. Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993 75 : 1169 78.
33. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997 34 : 577 82.
34. Sibley K, Rollinson S, Allan JM et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003 63 : 4327 30.
35. Kanemitsu S, Ihara K, Saifddin A et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002 29 : 1183 8 QR, Danis V, Lassere M et al. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999 38 : 645 51.
36. Lee YH, Kim YR, Ji JD et al. Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001 11 : 2008 11.
37. Ueda M, Terai Y, Kanda K et al. Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006 16 : 179 82.
38. Lai HC, Sytwu HK, Sun CA et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003 103 : 221 5.
39. Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 2004 112 : 1084 5.
40. Dybikowska A, Sliwinski W, Emerich J et al. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 2004 14 : 475 8.
41. Contreras DN, Krammer PH, Potkul RK et al. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother 2000 23 : 67 74.
42. Das H, Koizumi T, Sugimoto T et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000 82 : 1682 8.
43. Sun T, Miao X, Zhang X et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004 96 : 1030 6.
44. Ueda M, Hung YC, Terai Y et al. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005 98 : 129 33.
45. Dulic V, Kaufmann WK, Wilson SJ et al. p53 dependent inhibition of cyclin-dependent kinase activities in human fibroblast during radiation-induced G1 arrest. Cell 1994 76 : 1013 23.
46. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001 264 : 56 66.
47. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994 55 : 4855 78.
48. Ara S, Lee PS, Hansen MF et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990 18 : 4961.
49. Fan R, Wu MT, Miller D et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000 9 : 1037 42.
50. Liu G, Miller DP, Zhou W et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001 61 : 8718 22.
51. Miller DP, Liu G, De Vivo I et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 2002 62 : 2819 23.
52. Lee JM, Lee YC, Yang SY et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000 89 : 458 64.
53. Zehbe I, Voglino G, Wilander E et al. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999 354 : 218 19.
54. Roh JW, Kim JW, Park NH et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004 93 : 499 505.
55. Agorastos T, Masouridou S, Lambropoulos AF et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 2004 13 : 277 80.
56. Pegoraro RJ, Moodley M, Rom L et al. P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer 2003 13 : 444 9.
57. Wang Y, Kringen P, Kristensen GB et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004 24 : 21 34.
58. Ueda M, Terai Y, Kanda K et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006 100 : 173 8.
59. Matlashewski GJ, Tuck S, Pim D et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987 7 : 961 3.
60. Esteller M, Garcia A, Martinez-Palones JM et al. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997 75 : 1385 8.
61. Peller S, Halperin R, Schneider D et al. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 1999 6 : 193 7.
62. Ojeda JM, Ampuero S, Rojas P et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003 36 : 279 83.
63. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998 393 : 229 34.
64. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000 25 : 47 54.
65. Brooks LA, Tidy JA, Gusterson B et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000 60 : 6875 7.
66. Langerod A, Bukholm IR, Bregard A et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002 11 : 1684 8.
67. Tada M, Furuuchi K, Kaneda M et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001 22 : 515 17.
68. Honda T, Kato H, Imamura T et al. Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 1993 53 : 963 7.
69. Kihana T, Hamada K, Inoue Y et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 1995 76 : 72 8.
70. Niwa K, Murase T, Morishita S et al. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect Prev 1999 23 : 147 54.
71. Rosenthal AN, Ryan A, Al-Jehani RM et al. p53 codon 72 polymorphism and the risk of cervical cancer in UK. Lancet 1998 352 : 871 2.
72. Lanham S, Campbell I, Watt P et al. p53 polymorphism and risk of cervical cancer. Lancet 1998 352 : 1631.
73. Hayes VM, Hofstra RMW, Buys CHCM et al. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 1998 352 : 1756.
74. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004 13 : 11 22.
75. Nishikawa A, Fujimoto T, Akutagawa N et al. p53 polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 2000 10 : 402 7.
76. Ueda M, Hung YC, Terai Y et al. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis. Gynecol Oncol 2005 96 : 736 40.
77. Perego P, Giarola M, Righetti SC et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996 56 : 556 62.
78. Zastawny RL, Salvino R, Chen J et al. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993 8 : 1529 35.
79. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995 80 : 293 9.